Bruker Corporation (BRKR) Stock

Bruker Corporation (BRKR) is a Technology stock trading at $59.94 (as of 2026-08-20), with a market capitalization of $9.13B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Bruker Corporation develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions. It operates through segments including Life Science, Nano, and Energy & Supercon, providing tools such as mass spectrometry and molecular diagnostics kits, as well as research and process analysis instruments, X-ray and microscopy-related systems, and related detection solutions for customers in research and clinical settings.

Understand Bruker Corporation: how it makes money

Bruker develops and sells scientific instruments and analytical and diagnostic solutions, including life science tools such as mass spectrometry and pathogen identification platforms, plus nano systems and energy and supercon technologies, and it monetizes these offerings through product and system sales and related test kits and technologies.

Bruker’s profit engine is the combination of selling high-value scientific instruments and systems, with ongoing monetization tied to its platform and installed base products such as life science instruments, pathogen test platforms, and related test kits and technologies, while near-term results are influenced by order intake (book-to-bill).

Revenue by segment (latest quarter)
LifeSci	$0.5B
Nano	$0.3B
BEST	$0.1B

Business quality (Weak): Segments are aligned to Bruker’s three reportable areas using the provided revenue building blocks, and the operating view is supported by tracked order and installed-base metrics.

Bull case

Order intake signal: Scientific Instruments Book-to-Bill Ratio is 1.05, indicating new orders are slightly ahead of related revenue timing based on the company’s tracked ratio.
Platform and installed base focus: The company tracks installed base metrics (Multi-Biotypers Installed Base Units at 7000 and TIMSTOF Installed Base of Paid Units at 500), consistent with a business model that extends beyond one-time instrument sales.

Bear case

Low operating profitability: Operating margin is 1.2% for the latest period provided, which leaves less cushion if costs rise or demand softens.
Working capital drag risk: Cash Conversion Cycle (Days) is 253, indicating cash can be tied up in operations and may pressure near-term cash generation.

Valuation — source: SEC EDGAR (first-party)
Price	$59.94
Market Cap	$9.13B
EV / EBITDA	53.9
Price / Book	3.80
Price / Sales	2.61
FCF Yield	1.0%
DCF Value (model)	$15.20
DCF Upside vs Price	-74.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$3.44B
Net Margin	-0.3%
Revenue Growth (YoY)	5.2%
EPS Growth (YoY)	-920.0%
FCF Growth (YoY)	-28.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.75 (grey)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Sector P/E (Technology)	33.9
Industry P/E (Measuring & Control Equipment)	51.8

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Orbis Allan Gray Ltd ($648.00M)
Institutional Holders Tracked	10
Congressional Trades (recent)	2

Company
Sector	Technology
Industry	Measuring & Control Equipment
CEO	Frank H. Laukien
Employees	11,396
Country	US
IPO Date	2000-08-04

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.